此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Covered vs Bare Metal Stents for Atherosclerotic Renal Artery Stenosis (COMBAT)

2026年4月27日 更新者:Xiongjing Jiang、Chinese Academy of Medical Sciences, Fuwai Hospital

Endovascular Treatment of Atherosclerotic Renal Artery Stenosis: A Prospective Randomized Controlled Study Comparing Covered Stents and Bare Metal Stents

Atherosclerotic renal artery stenosis is the most common cause of secondary hypertension , increasing the risk of cardiovascular and kidney-related complications. Some small-scale studies have suggested that covered stents are effective and safe, but high-quality evidence from large-scale studies in atherosclerotic renal artery stenosis remains limited.

This study aims to evaluate whether covered stents are more effective than bare metal stents in patients with atherosclerotic renal artery stenosis. Eligible participants will be randomly assigned to receive either a covered stent or a bare metal stent. Patients will be followed for 12 months to assess Changes in eGFR, 24-hour systolic blood pressure, and 24-hour diastolic blood pressure from baseline to 12 months were compared among the groups.

The results of this study may help improve treatment strategies and guide the selection of stent type for patients with this condition.

研究概览

研究类型

介入性

注册 (估计的)

150

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Beijing、中国
        • Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037
        • 接触:
      • Chongqing、中国、400016
        • Department of Cardiovascular Medicine, Cardiovascular Research Center , The First Affiliated Hospital of Chongqing Medical University
      • Harbin、中国
        • The Second Affiliated Hospital of Harbin Medical University, Ha'erbin
        • 接触:
      • Jilin、中国、130033
        • China-Japan Union Hospital of Jilin University, Changchun, Lilin
        • 接触:
    • Guangdong
      • Guangzhou、Guangdong、中国、510000
        • The First Affiliated Hospital of Sun Yat-sen University
        • 接触:
    • Heilongjiang
      • Harbin、Heilongjiang、中国、150086
        • The Second Affiliated Hospital of Harbin Medical University
        • 接触:
    • Henan
      • Zhengzhou、Henan、中国、450000
        • Fuwai Central China Cardiovascular Hospital
      • Zhengzhou、Henan、中国、450007
        • Zhengzhou Central Hospital Affiliated to Zhengzhou University
        • 接触:
    • Jiangsu
      • Nanjing、Jiangsu、中国、211800
        • Nanjing Pukou People's Hospital(Liangjiang Hospital Southeast University)
    • Jiangxi
      • Nanchang、Jiangxi、中国、330038
        • Jiangxi Provincial People's Hospital (The First Affiliated Hospital of Nanchang Medical College)
    • Liaoning
      • Dalian、Liaoning、中国、116001
        • Affilated Zhongshan Hospital of Dalian University
      • Dalian、Liaoning、中国
        • Frist Aiffiliated Hospital of Dalian Medical University
    • Shandong
      • Jinan、Shandong、中国、250012
        • Qilu Hospital of Shandong University
      • Qingdao、Shandong、中国
        • Qingdao Hospital University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital)
    • Sichuan
      • Chengdu、Sichuan、中国、610031
        • The Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • 1) Renal artery diameter stenosis ≥60%; 2) Office systolic blood pressure ≥ 160 mmHg and/or office diastolic blood pressure ≥ 100 mmHg on at least two separate days without antihypertensive medication, or office systolic blood pressure ≥ 140 mmHg and/or office diastolic blood pressure ≥ 90 mmHg while on three antihypertensive drugs at conventional doses; 3) Serum creatinine < 264 μmol/L (3.0 mg/dL); 4) Affected kidney length ≥ 7.0 cm, with residual glomerular filtration rate (GFR) ≥ 10 mL/min;

Exclusion Criteria:

  • 1) Unstable clinical condition rendering the patient intolerant to revascularisation therapy; 2) Urinary protein ≥2+; 3) Contrast medium allergy; 4) Renal artery anatomy unsuitable for revascularisation therapy; 5) Reference vessel diameter <3.5mm or >8mm. 6)Patients with non-atherosclerotic renal artery stenosis (such as fibromuscular dysplasia or Takayasu arteritis); 7)Reference vessel diameter < 3.5 mm or > 8 mm

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器:bare metal stents group
Endovascular implantation of a bare metal stent in the renal artery.
实验性的:covered stents group
Endovascular implantation of a covered stent in the renal artery

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in eGFR
大体时间:12 months
Change in estimated glomerular filtration rate (eGFR) at 12 months compared with baseline
12 months

次要结果测量

结果测量
措施说明
大体时间
Change in 24-Hour Ambulatory Systolic Blood Pressure
大体时间:12 months
Change in 24-Hour Ambulatory Systolic Blood Pressure Compared With Baseline
12 months
Change in 24-Hour Ambulatory Diastolic Blood Pressure
大体时间:12 months
Change in 24-Hour Ambulatory Diastolic Blood Pressure Compared With Baseline
12 months
Change in Office Systolic Blood Pressure
大体时间:12 months
Change in Office Systolic Blood Pressure Compared With Baseline
12 months
Change in Office Diastolic Blood Pressure
大体时间:12 months
Change in Office Diastolic Blood Pressure Compared With Baseline
12 months
Change in Home Systolic Blood Pressure
大体时间:12 months
Change in Home Systolic Blood Pressure Compared With Baseline
12 months
Change in Home Diastolic Blood Pressure
大体时间:12 months
Change in Home Diastolic Blood Pressure Compared With Baseline
12 months
Change in antihypertensive medication burden
大体时间:12 months
Change in antihypertensive medication burden at 12 months compared with pre-procedure levels
12 months
Stent patency
大体时间:12 months
Stent patency at 12 months
12 months
Incidence of perioperative complications
大体时间:1 month
1 month
MACE
大体时间:12 months
Major adverse cardiovascular events (MACE) include cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure.
12 months
Renal Adverse Events
大体时间:12 months
Renal adverse events include a sustained decline in renal function (≥30% decrease in eGFR from baseline confirmed on repeat measurement), doubling of serum creatinine, initiation of renal replacement therapy (dialysis or kidney transplantation), or progression to end-stage renal disease.
12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年4月30日

初级完成 (估计的)

2027年4月30日

研究完成 (估计的)

2028年4月30日

研究注册日期

首次提交

2026年4月27日

首先提交符合 QC 标准的

2026年4月27日

首次发布 (实际的)

2026年5月4日

研究记录更新

最后更新发布 (实际的)

2026年5月4日

上次提交的符合 QC 标准的更新

2026年4月27日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅